Castle Biosciences Approved for Dual Listing on Nasdaq Texas

Castle Biosciences announced approval for a dual listing of its common stock on Nasdaq Texas, with trading expected to commence today under its existing ticker symbol CSTL. The company will maintain its primary listing on The Nasdaq Global Market, with management stating the move reflects the firm's Texas roots and supports visibility in the region's life sciences hub.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.